Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

0(0%)

Results Posted

120%(6 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_3

29%

Ph not_applicable

14%

Ph phase_1

14%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

3(42.9%)

Phase 3Large-scale testing

2(28.6%)

N/ANon-phased studies

1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(2)

Detailed Status

Completed5

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (14.3%)

Phase 23 (42.9%)

Phase 32 (28.6%)

N/A1 (14.3%)

Trials by Status

terminated114%

withdrawn114%

completed571%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_3

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

NCT00121108

completedphase_1

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

NCT00192504

completednot_applicable

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

NCT00421304

terminatedphase_2

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

NCT00435227

completedphase_2

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

NCT00316264

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT00121108Phase 3

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

Completed

NCT00192504Phase 1

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

Completed

NCT00421304Not Applicable

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

Completed

NCT00435227Phase 2

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Terminated

NCT00316264Phase 2

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Completed

NCT00628303Phase 3

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

Withdrawn

NCT00538785Phase 2

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Completed

All 7 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 7